Testing effectiveness (Phase 2)Study completedNCT00271765
What this trial is testing
INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
Who this might be right for
Acute Myocardial Infarction
Inotek Pharmaceuticals Corporation 40